Rosiglitazone Restores Endothelial Dysfunction in a Rat Model of Metabolic Syndrome through PPARγ- and PPARδ-Dependent Phosphorylation of Akt and eNOS
Vascular endothelial dysfunction has been demonstrated in metabolic syndrome (MS). Chronic administration of rosiglitazone ameliorates endothelial dysfunction through PPARγ-mediated metabolic improvements. Recently, studies suggested that single dose of rosiglitazone also has direct vascular effects...
Main Authors: | Zhigang Zhao, Zhidan Luo, Peijian Wang, Jing Sun, Hao Yu, Tingbing Cao, Yinxing Ni, Jing Chen, Zhencheng Yan, Daoyan Liu, Zhiming Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2011/291656 |
Similar Items
-
Lipid metabolome-wide effects of the PPARγ agonist rosiglitazones⃞
by: Steven M. Watkins, et al.
Published: (2002-11-01) -
PPARγ and PPARδ as Modulators of Neoplasia and Cell Fate
by: Robert I. Glazer, et al.
Published: (2008-01-01) -
Structure-based virtual screening and discovery of New PPARδ/γ dual agonist and PPARδ and γ agonists.
by: Vinicius G Maltarollo, et al.
Published: (2015-01-01) -
Phosphorylation of PPARγ Affects the Collective Motions of the PPARγ-RXRα-DNA Complex.
by: Justin A Lemkul, et al.
Published: (2015-01-01) -
Electroacupuncture Reduces Weight Gain Induced by Rosiglitazone through PPARγ and Leptin Receptor in CNS
by: Xinyue Jing, et al.
Published: (2016-01-01)